285 related articles for article (PubMed ID: 33907881)
1. Tissue distribution of epirubicin after severe extravasation in humans.
Nedomansky J; Haslik W; Pluschnig U; Kornauth C; Deutschmann C; Hacker S; Steger GG; Bartsch R; Mader RM
Cancer Chemother Pharmacol; 2021 Aug; 88(2):203-209. PubMed ID: 33907881
[TBL] [Abstract][Full Text] [Related]
2. Surgical management after doxorubicin and epirubicin extravasation.
Heitmann C; Durmus C; Ingianni G
J Hand Surg Br; 1998 Oct; 23(5):666-8. PubMed ID: 9821616
[TBL] [Abstract][Full Text] [Related]
3. Negative-pressure wound therapy and early pedicle flap reconstruction of the chest wall after epirubicin extravasation.
Papadakis M; Rahmanian-Schwarz A; Bednarek M; Arafkas M; Holschneider P; Hübner G
J Vasc Access; 2017 May; 18(3):e27-e29. PubMed ID: 28165571
[TBL] [Abstract][Full Text] [Related]
4. Contradistinction between doxorubicin and epirubicin: in-vitro interaction with blood components.
Ramanathan-Girish S; Boroujerdi M
J Pharm Pharmacol; 2001 Jun; 53(6):815-21. PubMed ID: 11428657
[TBL] [Abstract][Full Text] [Related]
5. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
6. Port-a-Cath extravasation of vesicant cytotoxics: surgical options for a rare complication of cancer chemotherapy.
Haslik W; Hacker S; Felberbauer FX; Thallinger C; Bartsch R; Kornauth C; Deutschmann C; Mader RM
Eur J Surg Oncol; 2015 Mar; 41(3):378-85. PubMed ID: 25515823
[TBL] [Abstract][Full Text] [Related]
7. Surgical management after doxorubicin and epirubicin extravasation.
Fleming A; Butler B; Gault D
J Hand Surg Br; 1999 Jun; 24(3):390. PubMed ID: 10433467
[No Abstract] [Full Text] [Related]
8. Epirubicin extravasation: consequences of delayed management.
Hale O; Deutsch PG; Lahiri A
BMJ Case Rep; 2017 Jan; 2017():. PubMed ID: 28062432
[TBL] [Abstract][Full Text] [Related]
9. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
Khasraw M; Bell R; Dang C
Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
[TBL] [Abstract][Full Text] [Related]
10. Conservative approach to the treatment of chemotherapy-induced extravasation.
Tsavaris NB; Karagiaouris P; Tzannou I; Komitsopoulou P; Bacoyiannis C; Karabellis A; Papanicolaou V; Mylonakis N; Karvounis N; Zoannou A
J Dermatol Surg Oncol; 1990 Jun; 16(6):519-22. PubMed ID: 2355131
[TBL] [Abstract][Full Text] [Related]
11. Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes.
Caballero Romero Á; Delgado Ureña MT; Salmerón García A; Megías Fernández MT; Librada Porriño-Bustamante M; Cabeza Barrera J
Anticancer Drugs; 2018 Oct; 29(9):821-826. PubMed ID: 30036190
[TBL] [Abstract][Full Text] [Related]
12. Treatment of anthracycline extravasation with dexrazoxane -- clinical experience.
Frost A; Gmehling D; Azemar M; Unger C; Mross K
Onkologie; 2006 Jul; 29(7):314-8. PubMed ID: 16874015
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.
Salvatorelli E; Menna P; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
J Pharmacol Exp Ther; 2012 May; 341(2):464-73. PubMed ID: 22338033
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer.
Bárdi E; Bobok I; V Oláh A; Kappelmayer J; Kiss C
Pathol Oncol Res; 2007; 13(3):249-53. PubMed ID: 17922055
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence microscopic demonstration and demarcation of doxorubicin extravasation. Experimental and clinical studies.
Dahlstrøm KK; Chenoufi HL; Daugaard S
Cancer; 1990 Apr; 65(8):1722-6. PubMed ID: 2317755
[TBL] [Abstract][Full Text] [Related]
16. [Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
Vasyuk YA; Shkolnik EL; Nesterov VV; Shkolnik LD; Varlan GV
Kardiologiia; 2016 Dec; 56(12):72-79. PubMed ID: 28290807
[TBL] [Abstract][Full Text] [Related]
17. Totect: a new agent for treating anthracycline extravasation.
Schulmeister L
Clin J Oncol Nurs; 2007 Jun; 11(3):387-95. PubMed ID: 17623623
[TBL] [Abstract][Full Text] [Related]
18. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.
Mouridsen HT; Langer SW; Buter J; Eidtmann H; Rosti G; de Wit M; Knoblauch P; Rasmussen A; Dahlstrøm K; Jensen PB; Giaccone G
Ann Oncol; 2007 Mar; 18(3):546-50. PubMed ID: 17185744
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
Danesi R; Fogli S; Gennari A; Conte P; Del Tacca M
Clin Pharmacokinet; 2002; 41(6):431-44. PubMed ID: 12074691
[TBL] [Abstract][Full Text] [Related]
20. Dexrazoxane for anthracycline extravasation.
Langer SW
Expert Rev Anticancer Ther; 2007 Aug; 7(8):1081-8. PubMed ID: 18028016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
